10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one
Hepatic Disease
Tanta UniversitySmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
44 Active assets in the Hepatic Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pioglitazone Yonsei University | Phase 4 | BBB |
Metformin Taipei City Hospital | Phase 4 | BBB |
Empagliflozin Military University Hospital, Prague | Phase 4 | BB |
Glibenclamide Takeda | Phase 4 | BB |
Metformin Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Phase 4 | BB |
View all 50 →
Same molecule, other indications
10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →